click enter text
still much uncertainti futur
invest summari stori opinion hing larg
degre compani abil remak consum
healthcar experi merger aetna time
drugstor industri throe signific chang futur along
futur drugstor model yet written believ
factor uncertainti well futur action like
amazon potenti disruptor like continu weigh
industri forese futur balanc factor strong
manag team low equiti valuat remain peer perform rate
trade fundament data
outlook adj ep estim move
respect page
quarter review market open past wednesday
report adj ep exceed estim revenu
slightli exceed forecast adj oper profit
exceed estim approx retail flash
wednesday page
valuat trade ntm consensu ep
estim low repres approx pro forma adj
ep reflect acquisit aetna valuat
long-term averag believ risk profil around
increas driven subdu growth stand-alone compani
uncertainti around potenti growth profil merg compani
note ep estim pro forma announc acquisit aetna
price et
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
under-perform broader market far calendar
compar rise calendar equiti fell compar rise
 calendar fell vs rise trade
ntm consensu ep compani averag
respect ev/ebitda basi trade close averag
averag respect
calendar year-end fair valu estim low unchang repres approxim
pro forma adj ep estim reflect announc acquisit aetna
continu believ use price-to-earnings multipl discount compani long-term price-to-earnings averag
appropri given number factor includ slow-down growth amazon entranc
pharmaceut dispens market potenti attrit exist pbm busi light
merger aetna uncertainti around cvs/aet consum health experi entail
growth profil combin busi time previous also reli
dcf analysi reflect intrins valu stand-alone basi given announc
merger aetna place emphasi pro forma earn analysi valu share
better pictur emerg long-term cash flow potenti pro forma merg compani
risk peer perform rate
risk upsid
equiti valuat histor averag inde equiti trade long-
term histor averag coupl dcf valuat stand-alone basi suggest
intrins valu well-abov equiti price posit news potenti translat higher equiti
price
win larg pbm contract similar downsid risk present loss larg pbm client
flipsid situat win larg pbm client could lead higher sale earn equiti price
strong manag team focus return organ stronger
growth team proven mani year strong steward busi
increasingli challeng landscap also return signific capit sharehold time
busi see challeng rebuild period sort believ team work
hard re-acceler growth compani abl sooner stronger fashion could lead
sale earn upsid rel current forecast potenti higher equiti price
page
produc signific cash flow focus enhanc sharehold return
multi-year period produc signific oper free cash flow help enterpris fund
grow dividend sizabl share repurchas annual believ compani oper model like
continu allow manag team return larg amount capit sharehold year
continu focus sharehold return next year like aberr return
capit sharehold due aetna acquisit suspens share repurchas program
lower leverag achiev howev busi perform expect would anticip
compani return capit sharehold may current anticip
announc acquisit aetna lead stronger growth profit combin basi
merger lead increas top-line growth less-than-anticip pbm client friction well stronger
profit part higher synergi could lead stronger earn higher valuat
thu higher equiti price time
risk downsid
growth profit outlook pro forma /aet enterpris lower-than-anticip
stand-alone compani also experienc subdu oper perform late particularli
pbm oper time embark path remak consum health experi
conjunct announc acquisit aetna remak experi take longer-than-anticip
could lead lower revenu earn growth synergi combin organ
lower-than-anticip need reinvest meaning busi could also
pressur oper result final pbm see more-than-anticip attrit client base and/or
amazon entranc industri via pillpack lead market share eros scenario would
diminish compani vertic model advantag last year competitor
teamed-up offer similar program offer like mainten choic part result
lose script retail pharmaci segment reaction allow retail platform bring
pbm healthcar plan certain program exclus caremark pbm
competitor continu success mimic vertic model and/or decis let retail pharmaci
busi partner compani result signific loss caremark competit stand
could detriment revenu growth profit time major pbm oper
particularli express script attempt carv retail pharmaci network could quit detriment
earn
increas government involv healthcar industri long-term believ
encroach govern healthcar industri remain largest risk ultim form
govern control would government-sponsor system idea float time time
certain constitu washington appear countri move toward single-payor
system even slowli direct public option could weigh valuat
need mani servic could wane time scenario would note
manag strongli believ much outlier event
page
amazon entranc industri greater-than-anticip impact cvss retail
pbm oper june amazon announc acquir pillpack signal amazon entranc
drug deliveri industri drug deliveri around time partner
usp challeng deal amazon go bundl good servic prime
benefit ecosystem bring lower-than-histor valuat like incorpor
risk amazon amazon abl garner greater-than-anticip market share sooner
anticip could lead pressur sale profit well equiti downsid
market share volum gain particularli health plan client materi
chang healthcar landscap health care plan play larger role marketplac
lower enterpris share health plan client rel employ client unabl increas
share script volum processed/dispens own asset health plan client could lead
subdu growth compani come year
enterpris profit growth less-than-anticip combin reimburs pressur busi
mix less increment benefit sourc gener like place pressur compani profit
margin near/medium-term vertic model time help mitig variou industri
headwind headwind becom greater-than-anticip profit could lower-than-expect
industri becom competit consum retail landscap pbm industri
remain competit action industri particip drive increas traffic retail drugstor
greater promot exampl attempt captur addit pbm client util price-driven strategi
could impact sale profit addit amazon acquisit pillpack entranc
industri like lead increas competit time
increas reimburs pressur lower reimburs rate continu place downward
pressur profit margin reimburs pressur increas current anticip
could place even pressur profit increas govern involv long-
term could exacerb margin pressur govern program account approxim
reimburs govern predisposit put pressur profit healthcar industri
broadli could see acceler deterior reimburs rate time
unexpect loss larg pbm contract health pbm busi maintain high client
retent rate howev unexpect loss larg pbm client would like pressur sale profit
compani
page
earn driver outlook
updat forecast follow second quarter earn adj ep
estim move respect third quarter
rais top-line growth expect consolid enterpris driven pharmaci
servic segment temper retail/ segment growth given challeng segment
profit perspect reduc oper profit growth expect total
enterpris driven less profit pharmaci servic segment partial off-set less profit pressur
retail/ltc segment fourth quarter forecast stronger consolid revenu growth
improv profit rel prior forecast combin better-than-expect second quarter
result reduc ep forecast stronger ep expect lead adj ep
in-lin prior forecast compar full year adj ep guidanc
chang made includ reduc oper profit lead adj ep
page
earn outlook tabl segment retail pharmaci consolid pharmaci consolid gross interseg segment total ebit consolid retail pharmaci consolid pharmaci interest expens interseg consolid gross incom net incom attribut ex retail pharmaci adj net incom cont op attribut ex pharmaci segment dilut ep attribut ex adj ep cont op attribut ex retail pharmaci pharmaci gener corpor weight average dilut share interseg ebit growth rate consolid gross retail pharmaci store ebit adj net incom cont op attribut ex adj ep cont op attribut ex pharmaci claim processedmail margin consolid retail pharmaci gross sg ebit average revenu mail retail pharmaci chang marginavg revenu gross sg ebit tax
quarter review
report better-than-expect result wednesday august market open
past wednesday morn report adj ep exceed estim
in-lin consensu prior guidanc consolid basi revenu
slightli exceed forecast retail pharmacy/ltc revenu in-lin forecast pharmaci
servic ahead forecast partial off-set higher interseg elimin consolid basi
adj oper profit exceed estim approx segment basi
retail pharmacy/ltc oper profit slightli lower/larg in-lin pharmaci servic approx
ahead forecast partial off-set lower interseg elimin lower corpor expens
retail pharmacy/ltc segment store sale exceed estim driven stronger
pharmaci comp sale narrow full-year guidanc adj oper profit growth
adj ep note
announc acquisit aetna anticip close third quarter earli fourth quarter
year equiti rose wednesday august sinc report pleas see retail
flash note follow earn result long-term uncertainti addit thought
page
wolfewolfey/ycurrentresearchactu vs y/ycurrentresearchactu vs quarterquarterestimatey/i estimatedquarterquarterestimatey/i estimatedearn tabl diffearn tabl segment difftot retail pharmaci consolid pharmaci consolid gross interseg segment total ebit consolid retail pharmaci consolid pharmaci interest expens interseg nmnmconsolid gross incom net incom attribut ex retail pharmaci adj net incom cont op attribut ex pharmaci segment dilut ep attribut ex adj ep cont op attribut ex retail pharmaci pharmaci gener corpor weight average dilut share interseg ebit margin consolid gross sg retail pharmaci store salesebit chang margingross margin retail pharmaci sg gross ebit sg ebit tax margin pharmaci servicesgross sg ebit chang margin retail pharmaci gross sg ebit chang margin pharmaci servicesgross sg ebit interseg eliminationsrevenu combin segment gross profit combin segment gross
